Sutro Biopharma
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | -13.4% | -25.7% | +11.2% | 0.0% | +44.8% | +9.5% | +126.8% | -59.6% | +65.2% | |
| – | +19.2% | +4.6% | +20.9% | +17.3% | -87.3% | -15.2% | -17.8% | +5.9% | +1.5% | |
| – | -101.0% | – | – | -180.1% | – | +14.2% | +147.0% | -62.7% | +73.6% | |
| – | +25.5% | -0.7% | +20.9% | +17.3% | +35.7% | +31.4% | +31.5% | +39.7% | -34.0% | |
| – | +10.5% | +30.6% | +52.4% | +13.0% | +52.1% | +6.3% | +5.1% | -22.6% | -15.3% | |
| – | +21.7% | +6.5% | +29.8% | -62.5% | +309.1% | +25.1% | +25.3% | +24.2% | -31.8% | |
| – | -1,512.9% | – | – | – | – | – | – | – | – | |
| – | – | +132.2% | +171.9% | -8.6% | -21.1% | +6.7% | +609.8% | +30.8% | +23.0% | |
| – | -1,256.8% | – | – | – | – | – | – | – | – | |
| – | +514.9% | +559.6% | +145.9% | -53.0% | -23.1% | -20.3% | +627.7% | -87.0% | -103.9% | |
| – | -1,256.8% | – | – | – | – | – | – | – | – | |
| – | -291.3% | – | – | – | – | – | – | – | – |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.